COLUMNS

Correspondence

The future of ECG monitoring - can psychiatry take the 'lead'?

Electrocardiogram (ECG) monitoring is an essential part of safe prescribing in psychiatry, especially when a patient is admitted to an acute in-patient ward in England. Any psychiatrist who has worked on such a ward will appreciate the challenges that come with completing this 'simple' investigation.

Despite it being almost 100 years since Willem Einthoven was awarded the Nobel prize 'for the discovery of the mechanism of the electrocardiogram' and almost 70 years since the American Heart Association published their recommendation for standardisation of 12-lead electrocardiogram, there have been few recent practical changes in the way ECGs are obtained in UK clinical practice.

Although 12-lead ECG machines have become smaller and more advanced, patients are still required to expose their chests; allow for all ten physical leads to be attached, often using uncomfortable or irritating stickers and clips; and lie still for several seconds while a reading is taken.

We recently completed a regional service evaluation across Yorkshire and the Humber examining ECG compliance on adult, older adult and forensic wards. Our data, gathered from 529 patients across 25 wards, demonstrated that only 82% (n = 432) of patients had an ECG at any point during admission, of which only 63% (n = 272) were completed in 24 h. Concerningly, among the patients taking antipsychotics (n = 378), these numbers were lower-80% (n = 303) and 50% (n = 188), respectively.

Qualitative analysis of results demonstrated that the most common reasons for not having an ECG completed were 'patient-related factors'. Where a specific reason was given, the most common were 'aggressive, agitated, anxious, paranoid' (159 of 257; 62%). ECGs can appear threatening and intrusive; clothes on the upper body need to be removed, body hair may need to be shaved and the chest leads can look frightening. When someone is already distressed, this fear is likely to be exaggerated. Anxiety, past physical and sexual abuse, or gender identity concerns may further exacerbate this.

ECG monitoring in psychiatry is safety driven and exists because antipsychotics (particularly at high doses),¹ some antidepressants and methadone can predispose to life-threatening heart arrhythmias.^{2,3} Examples include QTc prolongation, PR interval prolongation and, in extremis, torsade de pointes.¹ ECGs should be conducted as soon after admission as possible, preferably within the first 24 h.⁴ Our results show that patients are therefore at risk of potentially fatal side-effects, and prescribers fall short of evidence-based and guideline-directed practice.¹⁻⁴

Improving compliance with ECG monitoring, particularly in those prescribed pro-arrhythmic drugs, is a patient safety priority. Educating patients and mental health professionals about the need for ECGs is important, but reducing the intrusiveness and increasing the accessibility of ECG monitoring is called for.

116

Technological advancements are being embraced in other areas of psychiatric practice; why not extend this to ECG monitoring? The advent of handheld ECG machines could be a solution to ensure all patients receive high-quality safe healthcare. These devices are yet to be approved in the UK for measuring QTc, but early validation work seems positive.⁵

Jack Mumford (1), Liaison Psychiatry Specialty Doctor, Leeds and York Partnership NHS Foundation Trust, UK. Email: jack.mumford@nhs.net; Eimear Devlin, ST4 Old Age Psychiatry Humber Teaching NHS Foundation Trust, UK; George Crowther (1), Consultant Old Age Liaison Psychiatry, Leeds and York Partnership NHS Foundation Trust. Visiting Senior Lecturer, University of Leeds.

Declaration of interest

None

References

- 1 Joint Formulary Committee. Psychoses and related disorders. In *British National Formulary* (online). London: BMJ Group and Pharmaceutical Press. Available from: http://www.medicinescomplete.com (accessed on 22 May 2022).
- 2 Wu C-S, Tsai Y-T, Tsai H-J. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide casecrossover study. J Am Heart Assoc 2015; 4(2): e001568.
- 3 Zhu J, Hou W, Xu Y, Ji F, Wang G, Chen C, et al. Antipsychotic drugs and sudden cardiac death: a literature review of the challenges in the prediction, management, and future steps. *Psychiatry Res* 2019; 281: 112598.
- 4 Royal College of Psychiatrists. Standards for Inpatient Mental Health Services (2nd edn), CCQ1260 (eds Perry J, Palmer L, Thompson P, Worrall A, Chaplin R). RCPsych, 2017. Available from: https://www. rcpsych.ac.uk/docs/default-source/improving-care/ccqi/quality-networks/ learning-disability-wards-qnld/rcpsych-core-standards-inpatient-mentalhealth-services.pdf?sfvrsn=2d474631_2.
- 5 Azram M, Ahmed N, Leese L, Brigham M, Bowes R, Wheatcroft SB, et al. Clinical validation and evaluation of a novel six-lead handheld electrocardiogram recorder compared to the 12-lead electrocardiogram in unselected cardiology patients (EVALECG Cardio). *Eur Heart J Digit Health* 2021; 2(4): 643-8.

doi:10.1192/bjb.2023.7



© The Author(s), 2023. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creative-commons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

RE: Routine clozapine assay monitoring to improve the management of treatment-resistant schizophrenia

13 November 2022

Routine clozapine assay monitoring should start during initial titration of clozapine dosages

Kitchen and colleagues have published a very clinically relevant paper highlighting the importance of routine clozapine assays.¹ We would support their conclusion of increased use of routine monitoring using clozapine assays.

